CureVac Articles
Vaccines based on CureVac's RNActive technology demonstrate immunogenicity and protection against influenza
26 November 2012
Sanofi Pasteur and CureVac collaborate on a $33.1 million project on vaccines for infectious diseases
16 November 2011
Showing 1-2 of 2 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
